BioCentury
ARTICLE | Clinical News

Thalomid thalidomide: Phase II

June 9, 2003 7:00 AM UTC

In a U.S. Phase II study of Thalomid plus IL-2 in 37 patients, 2 of 36 evaluable patients had a complete response, 11 had a partial response and 6 had disease stabilization. Adverse events included se...